A new patient safety smartphone application for prevention of “forgotten” ureteral stents: results from a clinical pilot study in 194 patients
verfasst von:
Wilson R. Molina, Rodrigo Pessoa, Rodrigo Donalisio da Silva, McCabe C. Kenny, Diedra Gustafson, Leticia Nogueira, Mark E. Leo, Michael K. Yu, Fernando J. Kim
Approximately 12% of all ureteral stents placed are retained or “forgotten.” Forgotten stents are associated with significant safety concerns as well as increased costs and legal issues. Retained ureteral stents (RUS) often occur due to lack of clinical follow-up, communication or language barriers, and economic concerns.
Methods
We describe a multiplatform application that facilitates data collection to prevent RUS. The “Stent Tracker” application can be installed on mobile devices and computers. The encrypted and password-protected information is accessible from any device and provides information about each procedure, stent placement and removal dates, as well as product description. This multicenter retrospective study included 194 patients who underwent stent placement between July and October 2015. Nominal data was tallied and ordinal data was divided into quartiles of 25, 50, and 75%.
Results
A total of 194 patients from three institutions underwent ureteral stent placement. Reasons for stent placement include 122 cases post ureteroscopy (63%), 8 cases post percutaneous nephrolithotomy (PCNL) (4%), 14 cases post extracorporeal shock wave lithotripsy (SWL) (7%), 18 cases of cancer-related ureteral obstruction (9%), 21 cases of hydronephrosis (11%), and 11 for other reasons (6%). Of these patients, only one patient was lost to follow-up (0.5%). On average, ureteral stents were removed within 14 days of placement (IQR: 8-26 days).
Conclusions
The “Stent Tracker” is a patient safety application that provides a secure and simplified interface, which can significantly reduce the incidence of RUS. Further developments could include automated notifications to patients and staff, color-coding, and integrated information with electronic patient charts.
Abkürzungen
IQR
Interquartile range
PCNL
Pecutaneous nephrolithotomy
RUS
Retained ureteral stents
SWL
Extracorporeal shock wave lithotripsy
Background
Ureteral stents are an integral part of the treatment of different urological conditions such as nephrolithiasis, ureteral stricture, malignant obstruction, ureteral injury and healing [1, 2]. Retained ureteral stents (RUS) may cause infection, encrustation, and patient discomfort. Therefore, the use of ureteral stents require timely follow-up in order to avoid increased morbidity, mortality, and healthcare costs [3].
el-Faqih et al. reported that, following stents placed for urolithiasis, encrustation occurred in 9.2% of those removed under 6 weeks, 47.5% of those removed between six and 12 weeks, and 76.3% of those removed after 12 weeks [2]. Treating encrusted stents usually requires multiple procedures, significantly affecting costs. Sancaktutar et al. demonstrated that the cost of treatment for RUS was higher than a timely stent extraction and the financial burden of the treatments increased at the same rate as the duration of the stent retention (p = 0.001) [4].
Anzeige
Stent tracking systems based on patient registries have been used to reduce the incidence of RUS. Card-based versions of stent tracking, as described by Tang et al., have been advocated in the past but were largely replaced by electronic registries with automated reminders that link stent information to the patient’s electronic medical record [3, 5‐8]. Ather et al. reported a substantial decrease in the incidence of forgotten stents from 12.5 to 1.5% over the course of 1 year, making a strong case for the implementation of such systems into urological practice [5]. We describe a patient safety software that facilitates data collection to prevent RUS. To our knowledge, this is the first report of a smartphone-based platform for stent tracking in clinical practice.
Methods
The new application “Stent Tracker” was developed by Visible Health in partnership with Boston Scientific [9]. It aims to improve patient safety, facilitate data collection, and provide an efficient interface to simplify ureteral stent tracking. The “Stent Tracker” application can be downloaded from the Apple store and installed on mobile devices and computers. However, only Boston Scientific stents can be tracked in this application and its use is limited to physicians who are pre-authorized and registered by Boston Scientific. The encrypted and password-protected application provides information about each procedure, scheduled removal dates, and product description for Boston Scientific ureteral stents [10, 11]. (Figures 1 and 2). The application encrypts all data, both in transit and at rest. Visible Health uses Amazon Web Services for database encryption [10]. Visible Health’s security officer, privacy officer, and application administrator have access to data for maintenance and user support. Visible Heath’s privacy policy is compliant with Health Insurance Portability and Accountability Act (HIPAA). The password protected software offers three options: create a care plan, view care plan lists, and view the patient list. Creating a care plan is simplified by scanning the ureteral stent’s barcode. The software allows the healthcare provider to review all patient data divided into sections of overdue cases, incomplete cases (missing information), indwelling stents, and extracted stents.
Fig. 1
Snapshot of home screen of the “Stent Tracker” app
Fig. 2
Snapshot of patient profile page on the “Stent Tracker” app
×
×
The data was acquired from three institutions and a retrospective analysis was performed which included patients who had stents placed between July and October 2015. Stents were considered overdue when they were left in place for longer than anticipated. Nominal data were tallied; ordinal data were divided into quartiles of 25, 50, and 75%. Excel was used for descriptive analysis and data collection.
Results
An initial group of 194 patients from three institutions underwent ureteral stent placement and were subsequently tracked using the “Stent Tracker” application. The descriptive analysis on this introductory series is summarized in Table 1. Mean patient age was 55.9 (43–65) years. Indications for stent placement included 122 cases post ureteroscopy (63%), 8 cases post PCNL (4%), 14 cases post SWL (7%), 18 cases of ureteral cancer-related obstructions (9%), 21 cases of hydronephrosis (11%), and 11 for other reasons (6%). Overall, 149 stents were removed as planned (77%), 17 stents were overdue (9%), and 27 were scheduled to be removed by the time of this analysis (14%). The average dwelling time for the 149 removed stents was 14 days (IQR: 8–26 days). One patient was lost to follow-up because they were unable to be contacted and had no permanent address (0.5%).
Table 1
Patient demographics and ureteral stent data
Median (IQR)/Totals (%)
Cases (n)
194
Age (years)
55.9 (43–65)
Duration stented (days)
14 (8–26)
Side (n)
Left
Right
88 (46%)
105 (64%)
Stent Removal (n)
As planned
Overdue
Lost follow-up
Plan in-progress
149 (77%)
17 (9%)
1 (0.5%)
27 (14%)
Reason for stent placement (n)
Post ureteroscopy
Post PCNL
Post ESWL
Cancer
Hydronephrosis
Other
122 (63%)
8 (4%)
14 (7%)
18 (9%)
21 (11%)
11 (6%)
Anzeige
Discussion
Forgotten ureteral stents can result in severe encrustation which may require challenging interventional extraction methods [12]. Previous studies have suggested that 48% of stents may become encrusted within 3-months post placement, which emphasizes the need for close follow-up [13]. Multiple levels of patient safety should be implemented as it has been proven that education may not be sufficient to prevent RUS. Monga et al. reported that 10% of their patients with RUS will fail to show-up for scheduled stent removal despite being counseled by healthcare professionals [14].
In addition to the morbidity related to RUS, the increased financial burden is another significant problem. Sancaktutar et al. reviewed 27 medical files of patients with forgotten stents that were referred to their clinic between 2007 and 2010 [4]. The cost of treatment was estimated to be, on average, 6.9 times higher than a timely stent extraction due to the need for additional radiological studies, interventions, medical treatments, and extended hospital stay [4].
Over recent years, many centers have concentrated their attention on medico-legal litigation regarding forgotten ureteral stents [15]. Osman et al. published a summary of the collected data on urological litigation within the United Kingdom in 2011. The details of all successful claims pertaining to urology were retrieved between 1995 and 2009 from their national database. Forgotten ureteral stents accounted for the largest number of successful postoperative negligence claims: 23 claims in 14 years [15]. This overtly emphasizes the importance of thorough clinical assessment, record keeping, and follow-up with patients after stent placement. Ultimate responsibility for timely removal of ureteral stents has to be shared among the surgeon, health organizations, and the patient.
Investigators have reported different methods to reduce the incidence of RUS by using both manual and computerized systems [3, 5‐7]. McCahy et al. introduced their electronic system in 1991 to follow–up patients, which resulted in a reduction in late stent removal from 3.6 to 1.1% [16]. Ather et al. also noticed a reduction in the rate of overdue stents from 12.5 to 1.2% using an electronic stent tracker [5]. However, these systems had few advantages over the previously paper-based charts because they required manual data input and review.
Lynch et al. have popularized their electronic stent registration system that creates a case in the patient’s electronic chart whenever stent placement is documented and sets a mandatory maximum stent life [6]. When this period expires, the computer automatically sends email notices to medical personnel until the stent is removed and the database is updated. The main problem they encountered before introducing barcode technology was a low rate of data entry in the electronic registry; only 61% of the stents inserted in patients were being accurately quantified [6].
Subsequently, Sancaktutar et al. described the initial results of a computer-based system that tracks ureteral stents and automatically sends a reminder through a short message service (SMS) to both the patients’ and the urologists’ mobile phones [7]. A total of 186 patients received stents over an 11-month period, but only 108 were included in the group that was recalled by the stent extraction reminder program. The remaining patients were not included in the new system. From the designated due date to the time of stent removal, the mean delay was 307 ± 118.6 days in the group not participating in the project and 14.6 ± 2.06 days in the patients being tracked (p <0.0001) [7].
The use of a new application to track ureteral stents placed in 194 patients from different centers is described with the intent to reduce RUS. Only one patient was lost to follow-up and 9% of the stents were overdue at the time of removal, which marks significant improvement compared to previous reports. Conversely, median stent duration was similar to the best results from other series: 14 days (8–26). The application offers a safe, convenient manner for creating and following a list of patients, allowing information to be accessed as needed. Finally, the “Stent Tracker” facilitates data entry and may improve patient accountability and education preventing the incidence of forgotten stents.
Conclusion
The “Stent Tracker” application is a patient safety tool which provides an encrypted and simplified interface that can reduce the incidence of retained or “forgotten” stents. Ultimately, the goal would be the elimination of forgotten stents and the complications associated with them. Other potential features that may be included are automated alerts and notifications to patients and staff, color-coding, and integrated information with electronic patient charts. Further developments of universal patient tracking platforms should contribute to a culture of safety for Endourological procedures.
Anzeige
Acknowledgements
None.
Funding
None.
Availability of data and materials
The dataset is not publicly available but can be accessed by the authors of this manuscript in a protected and encrypted database.
Authors’ contributions
WRM, RDS, MCK, MEL, & MKY all contributed to data acquisition. WRM, MEL, MKY, and FJK coordinated to design and develop the concept of this manuscript. DG and LN organized and analyzed the data for this manuscript as well as submitted the final version of the manuscript. All authors participated in manuscript preparation as well as editing and revision. All authors read and approved the final manuscript.
Anzeige
Competing interests
Dr. Wilson R. Molina declares that he is a consultant for Boston Scientific.
Consent for publication
All authors have reviewed and approved the final version of the manuscript and have consented to allow DG and LN to submit to Patient Safety in Surgery.
Ethics approval and consent to participate
Since the use of the StentTracker application does not impact treatment, approval from an ethics committee is not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
